Unicycive Therapeutics, Inc.(UNCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

UNCY Unicycive Therapeutics, Inc.

Market Closed 05-15 16:00:00 EDT

8.26

-0.30

-3.50%

盘后8.38

+0.12+1.45%

19:49 EDT

High8.59	Low8.12	Vol828.70K
Open8.50	D1 Closing8.56	Amplitude5.49%
Mkt Cap220.54M	Tradable Cap200.56M	Total Shares26.70M
T/O6.87M	T/O Rate3.41%	Tradable Shares24.28M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"UNCY","market":"US","secType":"STK","nameCN":"Unicycive Therapeutics, Inc.","latestPrice":8.26,"timestamp":1778875200000,"preClose":8.56,"halted":0,"volume":828704,"hourTrading":{"tag":"盘后","latestPrice":8.38,"preClose":8.26,"latestTime":"19:49 EDT","volume":2583,"amount":21520.6504,"timestamp":1778888946252,"change":0.12,"changeRate":0.014528,"amplitude":0.014528},"delay":0,"changeRate":-0.0350467289719627,"floatShares":24280600,"shares":26700000,"eps":-2.108803,"marketStatus":"Market Closed","change":-0.3,"latestTime":"05-15 16:00:00 EDT","open":8.5,"high":8.59,"low":8.12,"amount":6869821.909952,"amplitude":0.054907,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.108803,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1779091200000},"marketStatusCode":7,"adr":0,"listingDate":1623988800000,"exchange":"NASDAQ","adjPreClose":8.56,"preHourTrading":{"tag":"盘前","latestPrice":8.5,"preClose":8.56,"latestTime":"09:29 EDT","volume":3118,"amount":27050.028156,"timestamp":1778851799999,"change":-0.06,"changeRate":-0.007009,"amplitude":0.043224},"postHourTrading":{"tag":"盘后","latestPrice":8.38,"preClose":8.26,"latestTime":"19:49 EDT","volume":2583,"amount":21520.6504,"timestamp":1778888946252,"change":0.12,"changeRate":0.014528,"amplitude":0.014528},"volumeRatio":1.6806319821002897,"impliedVol":2.1264,"impliedVolPercentile":0.8258},"requestUrl":"/m/hq/s/UNCY","defaultTab":"news","newsList":[{"id":"2635647050","title":"Assessing Unicycive Therapeutics (UNCY) Valuation As Q1 Loss Widens And FDA Decision On OLC Nears","url":"https://stock-news.laohu8.com/highlight/detail?id=2635647050","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635647050?lang=en_us&edition=fundamental","pubTime":"2026-05-16 14:40","pubTimestamp":1778913646,"startTime":"0","endTime":"0","summary":"Why Unicycive Therapeutics (UNCY) is Back on Investors’ Radar\nUnicycive Therapeutics (UNCY) has drawn fresh attention after reporting its first quarter 2026 results, showing a net loss of $12.82 million alongside ongoing FDA review of oxylanthanum carbonate with a June 29, 2026 PDUFA date.\nThis combination of a wider quarterly loss, preparations for a possible oxylanthanum carbonate launch, and a defined regulatory decision date is shaping how investors are reassessing the stock’s risk and...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uncy/unicycive-therapeutics/news/assessing-unicycive-therapeutics-uncy-valuation-as-q1-loss-w","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uncy/unicycive-therapeutics/news/assessing-unicycive-therapeutics-uncy-valuation-as-q1-loss-w","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","UNCY","LABU","BK4139","BK4585","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635476697","title":"Unicycive Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635476697","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635476697?lang=en_us&edition=fundamental","pubTime":"2026-05-14 11:02","pubTimestamp":1778727727,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryUnicycive Therapeutics Inc UNCY.OQ reported a quarterly adjusted loss of 54 cents per share for the quarter ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL8N41R04K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","UNCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635754594","title":"Unicycive Therapeutics publishes corporate presentation on kidney disease drug pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2635754594","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635754594?lang=en_us&edition=fundamental","pubTime":"2026-05-14 06:46","pubTimestamp":1778712371,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics highlighted oxylanthanum carbonate  as lead program for hyperphosphatemia in chronic kidney disease patients on dialysis, with an FDA PDUFA date of June 29, 2026, following acceptance of an NDA resubmission.NDA resubmission followed a late 2025 Type A meeting focused on resolving a compliance deficiency tied to a third-party manufacturing vendor cited in a complete response letter.Presentation framed hyperphosphatemia as a US market opportunity of more than USD 1 billion, citing about 550,000 US dialysis patients with roughly 80% receiving phosphate binders.In OLC pivotal safety population , treatment-related adverse events occurring in at least 5% of patients were diarrhea at 9% and vomiting at 6%, with no treatment-related serious adverse events.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational pur","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL2gnmRB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635384787","title":"Unicycive Therapeutics Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2635384787","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635384787?lang=en_us&edition=fundamental","pubTime":"2026-05-13 22:00","pubTimestamp":1778680800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/UNCY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 13, 2026 10:00 ET (14:00 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634821639","title":"Unicycive Therapeutics Q1 EPS $(0.54) Misses $(0.51) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2634821639","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634821639?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:48","pubTimestamp":1778586480,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.51) by 5.88 percent. This is a 8 percent decrease over losses of $(0.50) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52481360/unicycive-therapeutics-q1-eps-0-54-misses-0-51-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634954213","title":"Unicycive Therapeutics Q1 net loss widens on warrant liability","url":"https://stock-news.laohu8.com/highlight/detail?id=2634954213","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634954213?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:12","pubTimestamp":1778584373,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics Q1 net loss widens on warrant liabilityOverviewU.S. kidney disease biotech reported Q1 net loss widened mainly due to warrant liability changesR&D expense fell while G&A costs r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL1N41P0J0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634218702","title":"Unicycive Therapeutics Q1 Income From Operations USD -8.437 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634218702","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634218702?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:05","pubTimestamp":1778583900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nPLX70D8DB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","UNCY","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634138492","title":"Press Release: Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2634138492","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634138492?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:05","pubTimestamp":1778583900,"startTime":"0","endTime":"0","summary":"-- U.S. Food and Drug Administration  review of oxylanthanum carbonate.  New Drug Application  resubmission remains on track, with a. Prescription Drug User Fee Act  target action date of June 29,\"As we approach the June 29th PDUFA target action date, we remain optimistic about the potential approval of OLC and focused on preparations for the subsequent launch of OLC,\" said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. \"Our ongoing dialogue with the FDA during the review cycle has been constructive and timely. Uncontrolled hyperphosphatemia remains a significant health concern, affecting nearly 75% of U.S. patients with chronic kidney disease who are undergoing dialysis. OLC has the potential to improve adherence and phosphorus control with reduced pill burden, compared with currently available phosphate binders.\". a bioequivalence study in healthy volunteers, and a tolerability study in. patients with CKD on dialysis), multiple preclinical studies, and. continues to stren","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2746668461.USD","BK4585","LU0267386448.USD","LU0971096721.USD","BK4139","IE00B1BXHZ80.USD","IE00BZ1G4Q59.USD","LU2237443465.HKD","LU2237443549.SGD","LABU","UNCY","LU2746668974.SGD","BK4539","IE00BHPRN162.USD","CMC","BK4099","LU0170899867.USD","LU0882574139.USD","LU1363072403.SGD","TM","IE00BFXG1179.USD","IE00BKVL7J92.USD","ODD","BK4588","LU0149725797.USD","IE0009354923.USD","BK4604","LU2237443382.USD","LU2237443978.SGD","BK4555","LU2237443895.HKD","LU2237443622.USD","BK4006","03160","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634290518","title":"Unicycive swings to Q1 FY26 net loss of $12.82 million; operating expenses rise 6% to $8.44 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634290518","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634290518?lang=en_us&edition=fundamental","pubTime":"2026-05-12 18:32","pubTimestamp":1778581940,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics posted a net loss of USD 12.8 million, swinging from net income of USD 570,000 a year earlier.Operating loss widened 6% to USD 8.44 million as operating expenses climbed 6% to USD 8.44 million.General and administrative expense rose 17% to USD 6.83 million, while research and development expense fell 26% to USD 1.61 million.Other results turned to expense of USD 4.39 million from income of USD 8.56 million on a USD 4.78 million change in fair value of warrant liability.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Unicycive Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL4f1ZrT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNCY","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634346391","title":"Unicycive Therapeutics Inc  expected to post a loss of 51 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634346391","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634346391?lang=en_us&edition=fundamental","pubTime":"2026-05-09 00:16","pubTimestamp":1778256972,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics Inc  expected to post a loss of51cents a share - Earnings Preview Unicycive Therapeutics Inc UNCY.OQ UNCY.O is expected to  show no change in quarterly revenue when it reports  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L218:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNCY","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633950635","title":"Unicycive Therapeutics posts corporate presentation on kidney disease treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2633950635","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633950635?lang=en_us&edition=fundamental","pubTime":"2026-05-05 02:14","pubTimestamp":1777918464,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics highlighted lead phosphate binder candidate oxylanthanum carbonate  with FDA review of its resubmitted NDA underway under 505, carrying a June 29, 2026 PDUFA date.Resubmission followed a late 2025 Type A meeting focused on resolving a single CRL deficiency tied to compliance status at a third-party manufacturing vendor.Company framed OLC as a potential lower-pill-burden alternative to lanthanum carbonate therapy, with tablets designed to be swallowed whole rather than chewed.In OLC pivotal safety population , treatment-related adverse events at or above 5% were diarrhea 9% and vomiting 6%; discontinuations due to adverse events were 6%.Presentation cited cash runway into 2027 to support regulatory work, potential approval, and launch planning; it also highlighted UNI-494 in development for acute kidney injury.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDLbBPsLh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632610248","title":"B. Riley Initiates Unicycive Therapeutics at Buy With $22 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2632610248","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632610248?lang=en_us&edition=fundamental","pubTime":"2026-05-01 22:10","pubTimestamp":1777644621,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics (UNCY) has an average rating of buy and mean price target of $41.33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ma","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631529635","title":"Unicycive Therapeutics announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2631529635","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631529635?lang=en_us&edition=fundamental","pubTime":"2026-04-30 19:01","pubTimestamp":1777546898,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics will hold its annual shareholder meeting in Mountain View, California on June 19, 2026.Shareholders will vote on election of three directors to serve until 2027 annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Unicycive Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 30, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL1rbqkQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNCY","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625674558","title":"Unicycive director Gaurav Aggarwal resigns from board","url":"https://stock-news.laohu8.com/highlight/detail?id=2625674558","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625674558?lang=en_us&edition=fundamental","pubTime":"2026-04-06 21:12","pubTimestamp":1775481148,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics reported resignation of director Gaurav Aggarwal from board effective April 6, 2026.Aggarwal’s departure was not tied to any disagreement with management or board on operations, policies, or practices.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Unicycive Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nNDL8WvPqg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625567147","title":"Unicycive Therapeutics Is Maintained at Speculative Buy by Benchmark","url":"https://stock-news.laohu8.com/highlight/detail?id=2625567147","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625567147?lang=en_us&edition=fundamental","pubTime":"2026-04-06 20:53","pubTimestamp":1775479980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/UNCY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 06, 2026 08:53 ET (12:53 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625676081","title":"Unicycive Therapeutics price target lowered to $15 from $21 at Benchmark","url":"https://stock-news.laohu8.com/highlight/detail?id=2625676081","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625676081?lang=en_us&edition=fundamental","pubTime":"2026-04-06 19:30","pubTimestamp":1775475008,"startTime":"0","endTime":"0","summary":"Benchmark lowered the firm’s price target on Unicycive Therapeutics (UNCY) to $15 from $21 and keeps a Speculative Buy rating on the shares. After ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-price-target-lowered-to-15-from-21-at-benchmark-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-price-target-lowered-to-15-from-21-at-benchmark-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624029285","title":"Unicycive Therapeutics Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2624029285","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624029285?lang=en_us&edition=fundamental","pubTime":"2026-04-02 22:01","pubTimestamp":1775138460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/UNCY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 02, 2026 10:01 ET (14:01 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624529503","title":"Unicycive Therapeutics price target lowered to $40 from $46 at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2624529503","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624529503?lang=en_us&edition=fundamental","pubTime":"2026-04-02 18:59","pubTimestamp":1775127569,"startTime":"0","endTime":"0","summary":"Guggenheim lowered the firm’s price target on Unicycive Therapeutics (UNCY) to $40 from $46 and keeps a Buy rating on the shares. The firm made “re...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-price-target-lowered-to-40-from-46-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-price-target-lowered-to-40-from-46-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624780548","title":"Unicycive publishes corporate presentation highlighting OLC NDA review ahead of June 29 PDUFA date","url":"https://stock-news.laohu8.com/highlight/detail?id=2624780548","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624780548?lang=en_us&edition=fundamental","pubTime":"2026-04-02 01:04","pubTimestamp":1775063054,"startTime":"0","endTime":"0","summary":"Unicycive highlighted oxylanthanum carbonate  as lead program for hyperphosphatemia in chronic kidney disease patients on dialysis, with NDA resubmission under FDA review.FDA assigned June 29, 2026 PDUFA date for OLC following acceptance of resubmission tied to remediation at third-party manufacturing vendor.Company positioned OLC for potential launch, citing priorities in market awareness, reimbursement access, commercial operations.Presentation cited hyperphosphatemia as US market opportunity above $1 billion, with more than 550,000 US dialysis patients.Unicycive projected cash runway into 2027 to support OLC review, potential approval, launch preparations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Unicycive Therapeutics Inc. pu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL2n6HDD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNCY","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623312951","title":"Unicycive Therapeutics Q4 EPS $(0.82) Misses $0.03 Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2623312951","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623312951?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:53","pubTimestamp":1774871623,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.82) per share which missed the analyst consensus estimate of $0.03 by 2511.76 percent. This is a 68.46 percent increase over losses of $(2.60) per","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51535325/unicycive-therapeutics-q4-eps-0-82-misses-0-03-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNCY"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.unicycive.com","stockEarnings":[{"period":"1week","weight":0.0403},{"period":"1month","weight":0.1851},{"period":"3month","weight":0.3323},{"period":"6month","weight":0.4568},{"period":"1year","weight":0.5002},{"period":"ytd","weight":0.4315}],"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":0.056},{"period":"3month","weight":0.0842},{"period":"6month","weight":0.1001},{"period":"1year","weight":0.2519},{"period":"ytd","weight":0.084}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.078139},{"month":2,"riseRate":0.6,"avgChangeRate":0.088088},{"month":3,"riseRate":0.4,"avgChangeRate":0.59683},{"month":4,"riseRate":0.4,"avgChangeRate":-0.11937},{"month":5,"riseRate":0.6,"avgChangeRate":-0.03757},{"month":6,"riseRate":0,"avgChangeRate":-0.181228},{"month":7,"riseRate":0,"avgChangeRate":-0.103059},{"month":8,"riseRate":0.2,"avgChangeRate":-0.122604},{"month":9,"riseRate":0.6,"avgChangeRate":0.038818},{"month":10,"riseRate":0.8,"avgChangeRate":0.050976},{"month":11,"riseRate":0.6,"avgChangeRate":0.060673},{"month":12,"riseRate":0.4,"avgChangeRate":0.09852}],"exchange":"NASDAQ","name":"Unicycive Therapeutics, Inc.","nameEN":"Unicycive Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Unicycive Therapeutics, Inc.(UNCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Unicycive Therapeutics, Inc.(UNCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Unicycive Therapeutics, Inc.,UNCY,Unicycive Therapeutics, Inc.股票,Unicycive Therapeutics, Inc.股票老虎,Unicycive Therapeutics, Inc.股票老虎国际,Unicycive Therapeutics, Inc.行情,Unicycive Therapeutics, Inc.股票行情,Unicycive Therapeutics, Inc.股价,Unicycive Therapeutics, Inc.股市,Unicycive Therapeutics, Inc.股票价格,Unicycive Therapeutics, Inc.股票交易,Unicycive Therapeutics, Inc.股票购买,Unicycive Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Unicycive Therapeutics, Inc.(UNCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Unicycive Therapeutics, Inc.(UNCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}